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EDITORIAL REVIEW
Lipid abnormalities in uremia, dialysis, and transplantation
The institution of renal replacement therapy has
sustained the lives of many patients with end-stage
renal failure and has made it possible to study in
depth the metabolic abnormalities associated with
the uremic state. An important consequence of
chronic uremia is the development of lipid abnor-
malities [1, 2], which continue to affect many pa-
tients on dialysis [1, 3, 4] and after renal transplan-
tation [5—7]. There has been tremendous interest in
lipid metabolism in chronic renal failure, especially
after the provoking report of Lindner et al that
dialysis accelerates atherosclerosis [8]. Cardiovas-
cular deaths still claim many lives on dialysis [7]
and after transplantation [9, 10]. We realize hyper-
lipidemia is only one, and may not be the most
important one, of the risk factors in the develop-
ment of ischemic heart disease in patients with
uremia and shall restrict ourselves to the review of
the current understanding of the pathogenesis of
hyperlipidemia in uremic, dialysis, and renal trans-
plant patients. Two basic processes regulate plasma
triglyceride concentrations: triglyceride production
and triglyceride removal. The factors potentially
capable of affecting each process are enumerated in
Table 1, and in the discussion that follows we shall
try to evaluate their relative contributions to hyper-
lipidaemia in uremic patients.
Lipid abnormalities in uremia. Hypertriglyceri-
demia is the major lipid abnormality and occurs in
20 to 70% of dialyzed and undialyzed patients with
uremia [3, 4, 11—14] (Table 2). The predominant
lipoprotein pattern is type IV according to Freder-
ickson's classification [15], with elevation of very-
low-density lipoproteins (VLDL). Alterations in the
composition of major lipoprotein fractions exist
with increase in the triglyceride content of VLDL
and low-density lipoproteins (LDL) and decrease in
the cholesterol content of high-density lipoproteins
(HDL) [16—17]. LDL cholesterol, however, remains
normal. Because HDL cholesterol has been con-
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vincingly demonstrated to be a "protective" factor
against ischemic heart disease in epidemiologic
studies [18], the apoprotein composition of HDL
has been studied in some detail. Apo-Al, the major
apoprotein of HDL, has been reported as normal in
patients on maintenance dialysis [161 whereas apo-
CII, a minor but functionally important apoprotein
of HDL, is significantly reduced [14]. The subfrac-
tions of HDL, such as HDL2 and HDL3, have not
been studied.
Influence of underlying renal disease on lipid
metabolism. Patients with uremia represent a heter-
ogenous collection. The etiologies of their underly-
ing renal disease are diverse. It appears, however,
that the cause of renal disease has no significant
influence on the lipid abnormalities when the pa-
tient reaches end-stage renal failure. For example,
identical alterations in the composition of individual
lipoproteins occur in patients with documented
chronic glomerulonephritis and in those with surgi-
cal nephrectomies [19], and no differences could be
detected in serum triglyceride concentrations be-
tween patients with chronic glomerulonephritis and
polycystic disease, respectively [16]. Because only
patients in end-stage renal failure who are not
obviously nephrotic are considered in this review,
patients with uremia will be treated as a group to
avoid undue repetition when the various pathoge-
netic factors are discussed. Findings pertinent to a
particular group of patients will be indicated wher-
ever appropriate.
Triglyceride removal. As mentioned previously,
hypertriglyceridemia is the result of increased tri-
glyceride production or decreased triglyceride re-
moval, or both. The relative roles of triglyceride
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Table 1. Putative factors in the pathogenesis of hyperlipidemia in uremia
A. Decreased triglyceride removal
1. Depressed lipoprotein lipase activity
a. Decreased synthesis of lipoprotein lipase due to insulin resistance
b. Decreased releasable pool of lipoprotein lipase due to repeated heparinization
c. Decreased activator concentrations (low apo-Cli/apo-Cill ratio)
d. Presence of nonspecific "uremic toxins" as lipoprotein lipase inhibitors
2. Decreased hepatic lipase activity
3. Decreased lecithin-cholesterol-acyl-transferase (LCAT) activity
a. Decreased LCAT concentration
b. Decreased concentration of preferred substrate HDL
c. Decreased activator: apo-Al
d. Presence of nonspecific "uremic toxins" as enzyme inhibitors
4. Impaired beta-oxidation of free fatty acids due to carnitine deficiency
5. Hormonal factors, for example, hypothyroidism
B. Increased triglyceride production
1. Dietary carbohydrste
2. Glucose and acetate in dialysis fluid
3. Increased lipolysis due to increased concentrations of glucagon, growth hormone, and insulin resistance; increased hepatic
extraction of free fatty acids due to decreased binding capacity of albumin
4. Hyperinsulinemia.
5. Decreased beta-oxidation of free fatty acids
6. Drugs, for example, oestrogens and androgens
Table 2. Lipoprotein phenotypes in uremic, dialysis, and renal transplant patientsa
production and removal in the pathogenesis of
uremic hypertriglyceridemia remain controversial.
Using techniques ranging from the clearance of
exogenous chylomicron preparations (Intralipid) in
a bolus injection [20, 21] or in an infusion [22] to
turnover studies using tritiated glycerol [23], sever-
al groups of workers have demonstrated a defect in
triglyceride removal. Removal of Intralipid follows
first-order kinetics [24, 25], and as the fractional
clearance rate of Intralipid (K2) is readily obtained
from fat tolerance tests, we shall frequently refer to
this rate constant in our discussion of triglyceride
removal. A significant inverse correlation exists
between serum triglyceride concentrations and K2
(Fig. 1). The correlation is also clearly hyperbolic in
hemodialysis patients when K2 is obtained after
heparin administration [211. It therefore appears
likely that for patients with a high K2, triglyceride
removal has to be grossly reduced before there is
any appreciable change in serum triglyceride con-
centrations. On the other hand, relatively small
reductions in triglyceride removal could bring about
large increases in serum triglyceride concentrations
in patients with a low K2. Chylomicrons and VLDL
share the same degradative pathway [261, and it
might be argued that the grossly reduced K2 reflects
competition between Intralipid and endogenous
VLDL for enzymatic degradation, thereby artefac-
tually reducing K2. Such an explanation is difficult
to reconcile with the finding of reduced K2, albeit to
a lesser extent, in normotriglyceridemic uremic
patients. Furthermore, K2 and serum triglyceride
concentrations do not always undergo reciprocal
changes [25]. Although Intralipid should not be
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a Abbreviations are defined as follows: ESRF, end-stage renal
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failure, undialyzed; PD, intermittent peritoneal dialysis; HD,
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taken as identical with chylomicrons, SK2 has been
shown to correlate well with the fractional turnover
rate of endogenous triglycerides [25] and the turn-
over rate of apoprotein B [27], a major apoprotein
of VLDL and chylomicrons. It is therefore reason-
ably safe to assume that the low K2 does represent
reduced triglyceride removal in uremia. Indeed, the
altered composition [16, 19] of individual lipopro-
teins, for example, the high triglyceride content of
LDL, is probably the result of defective triglyceride
catabolism.
Lipolytic activity after heparin ad,ninistration.
What causes the reduced triglyceride removal in
uremia? Triglycerides in chylomicrons and VLDL
are hydrolyzed by lipoprotein lipase (LPL) situated
at the endothelial surface of extrahepatic tissues,
mainly muscle and adipose tissue. Intermediate
density lipoproteins or "remnant" particles are
formed, and these are further catabolized by hepat-
ic lipase (HTGL) to form LDL [28]. Lipoprotein
lipase requires apo CII for activation [29]. Apo CII
shuttles between the triglyceride-rich particles and
the high-density lipoproteins, which serve as a
reservoir of the activator [30]. The excess polar
surface material of VLDL and chylomicrons is dealt
with by the action of lecithin-cholesterol-acyl trans-
ferase (LCAT), and as the "core" triglycerides are
hydrolyzed, some of the surface apoproteins are
transferred to HDL [31]. It is clear that there are
many steps at which triglyceride removal can po-
tentially be affected, in particular, the concentra-
tions of the two lipases and their activators or
inhibitors. Because LPL and HTGL are normally
not in measurable concentrations in plasma, hepa-
rin has been widely used to release these enzymes
into circulation for the in vitro assay of their activi-
ties [32, 33]. Earlier studies [1, 22, 34] of total
postheparin lipolytic activity have consistently
shown reduced enzyme activities in uremic plasma
in spite of the different doses of heparin adminis-
tered. Measurements of the two lipases in posthepa-
nfl plasma have yielded conflicting results [35—38].
Some workers have reported a selective hepatic
lipase deficiency [35, 36] in dialyzed and undialyzed
uremic patients. If the observed impairment in
hepatic lipase has physiologic implications, it might
be expected that the predominant lipoprotein pat-
tern in uremia is type III with the accumulation of
remnant particles. This is contrary to the finding of
type IV hyperlipoproteinemia in most studies, al-
though it might partly explain the high triglyceride
content of VLDL and LDL in uremic patients.
Other workers have found that although lipopro-
tein lipase is reduced in both male and female
patients with uremia, hepatic lipase is significantly
reduced only in uremic males [37]. Although differ-
ences in patient selection and assay conditions may
account for some of these discrepancies, it must be
appreciated that because lipoprotein lipase consti-
tutes a small fraction of the lipolytic activity in
postheparin plasma [32, 33, 38], differences in lipo-
protein lipase might be more difficult to detect,
particularly if the method involves subtraction of
one enzyme activity from the total lipolytic activity.
Applebaum-Bowden et al [39], studying only male
patients on regular hemodialysis, have also con-
firmed that hepatic lipase activity is reduced. But,
they have also found that lipoprotein lipase activity
is significantly reduced and, although no difference
in hepatic lipase exists between normo- and hyper-
triglyceridemic patients, the latter have significant-
ly lower lipoprotein lipase activities. In animal
experiments, after injection of an antiserum to
lipoprotein lipase [40], there is a sharp rise in
plasma triglyceride concentrations, whereas in
similar experiments using antiserum to hepatic li-
pase [41], a rise in triglyceride concentration is
observed only after a lag phase of 2 hours. The
finding that when hypertriglyceridemia in dialysis
patients is reduced with clofibrate, lipoprotein li-
pase activity increases but hepatic lipase activity
remains unchanged [42], strongly suggests that lipo-
protein lipase plays a more important role than
hepatic lipase in the pathogenesis of uremic
hypertriglyceridemia. Whether the reduced lipopro-
tein lipase activity in patients with uremia is the
result of impaired synthesis of the enzyme by
muscle or adipose tissue, remains to be determined.
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Fig. 1. Correlation between K2 (Intralipid) and serum triglycer-
ide concentrations. Open circles represent normal subjects and
closed circles undialyzed uremic subjects with creatinine clear-
ance less than 15 mI/mm (Chan eta!, unpublished). Evidently the
relation between the two parameters is hyperbolic.
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Lipoprotein lipase activators/inhibitors and
HDL. The exogenous chylomicrons of Intralipid do
not contain apo-C class apoproteins, and presum-
ably acquire the activator apoprotein from HDL in
vivo. A reduced K2 could therefore be the result of
reduced activator or enzyme (lipoprotein lipase)
concentrations or increased inhibitor concentra-
tions. In subjects without uremia, a good correla-
tion exists between K2 and lipoprotein lipase 11431.
The apparent controversy between the finding of
reduced K2 in uremic patients by some workers and
normal lipoprotein lipase activities by others, could
be explained by the inclusion of normal serum as a
source of lipoprotein lipase activator in in vitro
assay systems, thereby removing any rate-limiting
effect of the activator in uremic serum. Although it
has been demonstrated that activator concentration
is not rate-limiting in hypertriglyceridemic patients
with presumably normal renal function [441, the
same has not yet been established for uremic pa-
tients. On the contrary, reduced apo-ClI in HDL
and VLDL [14] and reduced apo-CIl/Ill [45] ratios
have been reported in dialysis patients. It is con-
ceivable that a relative deficiency of apo-Cli or
relative excess of apo-Cill could contribute to
hypertriglyceridemia, as has been reported in indi-
vidual cases [46, 47]. As mentioned previously,
HDL cholesterol concentrations in uremic patients
tend to be low whereas triglyceride concentrations
tend to be high. The inverse relationship between
HDL cholesterol and triglyceride concentration is
attributed by some to decreased catabolism of
VLDL and chylomicrons [48]. The positive correla-
tion between HDL cholesterol and lipoprotein li-
pase [481 activity is consistent with this view. But,
because HDL is an important reservoir for apo-Cil,
low HDL cholesterol levels might reflect low acti-
vator concentrations and are therefore the cause,
rather than the result, of the reduced triglyceride
removal. Further studies are needed to resolve this
enigma, although the finding of a significant positive
correlation between HDL cholesterol and K2 after,
but not before, the administration of heparin in
dialysis patients favors the latter point of view [211.
The human intestine is capable of synthesising apo-
Al [49], the major apoprotein of HDL. The relative
roles of hepatic and intestinal secretion of this
important lipoprotein in uremia remain completely
unexplored.
Hormonal factors. Because the kidney is impor-
tant in the degradation of peptide hormones, it is
not surprising to find increased concentrations of
various peptide hormones in uremia. The relevance
of these findings to lipid metabolism is uncertain.
Although it is known that hypothyroid patients have
defective triglyceride removal [50], the low thyrox-
ine concentrations found in uremic plasma and the
deranged hypothalamic-pituitary-thyroid axis [511
are still biochemical curiosities. No differences in
various indices of thyroid function are observed
between hyper- and normo-lipemic uremic patients
by some workers [521. although others [16] have
reported that dialysis patients with hypothyroidism
(defined by low T4/T3 with raised TSH) have signif-
nificantly higher serum triglyceride concentrations
than do euthyroid dialysis patients. Hyperglucagon-
emia [11, 53] has been demonstrated in uremia.
Although it is suggested that glucagon inhibits lipo-
protein synthesis by the liver [54], it is doubtful
whether glucagon resistance [55] has a role to play
in the pathogenesis of uremic hypertriglyceridemia.
Increased glucagon concentrations may simply be
the result of decreased breakdown and clearance by
the kidney, and the hormone fragments may not be
metabolically active. Kuku et al have shown that in
uremia there is elevation of three glucagon frag-
ments, with the greatest rise in the 9000-dalton
fragment, which is not found in normal fasting
subjects [56]. Thus, although glucagon is a known
potent stimulator of lipolysis, free fatty acid (FFA)
concentrations in uremic patients are often normal
or low [2, 20, 57], although one group of workers
[57] have reported increased plasma glycerol con-
centrations in nondialyzed patients with uremia.
Insulin resistance is thought to play a pivotal role in
the pathogenesis of various hypertriglyceridaemic
states [58]. Bagdade, Porte, and Bierman et a!
postulated that hyperinsulinism contributed to ure-
mic hyperlipoproteinemia, probably by increasing
hepatic triglyceride synthesis [11. The positive cor-
relation between immunoreactive insulin concen-
trations and plasma triglyceride concentrations [1,
201 does not necessarily imply increased triglycer-
ide synthesis, although it probably reflects the
degree of peripheral insulin resistance in hypertri-
glyceridemia. Although it has been demonstrated
that there is resistance to the action of insulin in
stimulating glucose uptake in uremia [59], it remains
to be shown that this resistance extends to the
stimulating effect of insulin on lipoprotein lipase
synthesis [60]. We have obtained indirect evidence
that this probably occurs in some patients. K2
(Intralipid) in dialysis patients (HD + PD) is in-
versely related to plasma immunoreactive insulin
levels (unpublished observations). Thus, patients
with higher fasting levels of immunoreactive insu-
Lipid abnormalities in uremia 629
tin, and presumably a greater degree of insulin
resistance, have a lower K2. Although pro-insulin
could conceivably account for some of the immu-
noreactivity of insulin, it is unlikely that it could be
responsible for these correlations. The low concen-
trations of lipoprotein lipase in adipose tissue from
uremic patients also provide circumstantial evi-
dence for such insulin resistance [61, 62]. Elevated
growth hormone [57] and parathyroid hormone
through its effect on plasma calcium concentrations
[63] probably also contribute to insulin resistance.
The role of growth hormone requires further inves-
tigation because the growth hormone response to
glucose load is paradoxical [641 in dialysis patients.
The contributions of parathormone, if any, may be
overshadowed by other influences, for patients
remain hypertriglyceridemic after total para-
thyroidectomy (unpublished observations).
Triglyceride production and the role of diet. The
question of whether triglyceride production is ele-
vated in uremia cannot be answered with certainty.
Short of direct catheterization of the hepatic vein or
blocking peripheral triglyceride removal and mea-
suring the rise in serum triglyceride concentrations,
there is no satisfactory method for quantifying
triglyceride production [65]. Studies with labeled
glycerol or free fatty acids are weakened by the
questionable assumption that triglyceride turnover
follows first-order kinetics. At least three such
studies [66—68] have been performed in nondialyzed
uremic patients, all of which demonstrated reduced
fractional and increased total turnover rate of tri-
glycerides. Unfortunately, the normal values re-
corded for the normolipemic control subjects in
Nikkila's study [69] have often been extrapolated to
the hypertriglyceridemic range to provide an imagi-
nary reference frame. Although it is true that tri-
glyceride turnover rates in uremic patients may not
be elevated above those of hypertriglyceridemic
nonuremic subjects, it is true that triglyceride turn-
over rates are higher in hypertriglycericlemic uremic
patients when compared with those of normotrigly-
ceridemic uremic or normotriglyceridemic control
subjects (Fig. 2). In the steady state, it is difficult to
ascertain whether increased triglyceride production
is the initiating event in hypertriglyceridemia. The
finding of low normal [2, 20, 57] plasma concentra-
tions of free fatty acids in uremia does not favor the
concept of increased triglyceride production be-
cause it is generally accepted that in the fasting
state plasma free fatty acids provide the major
substrate for hepatic triglyceride synthesis. But the
hepatic extraction of FFA in uremia may be en-
Fig. 2. Relation between serum triglyceride concentrations and
triglyceride turnover rates in normal and uremic subjects. (From
Cattran et a! 1231, Cramp et al [661, and Verschoor et al [681).
Open circles represent normal subjects. It is clear that total
triglyceride turnover rate is a curvilinear function of serum
triglyceride concentrations. The curve is drawn for the normal
subjects only. Closed circles represent hemodialysis patients and
"targets" ® peritoneal dialysis patients (from Cattran et al
[23]). Crosses (Verschoor et al [68]) and solid triangles (Cramp et
al [66]) represent undialyzed uremic patients with creatinine
clearances from 2.9 to 37 mI/mm. Widely different values were
obtained by the two groups of workers in undialyzed uremic
subjects. Nevertheless, it is clear that hypertriglyceridemic
subjects in general have higher triglyceride turnover rates than
do their normotriglyceridemic counterparts. The normal values
are taken from Refs. 23 and 68.
hanced, for the binding capacity of albumin in
uremic plasma is decreased [70]. Significant posi-
tive correlations between plasma immunoreactive
insulin and serum triglyceride concentrations have
also been reported in dialyzed and undialyzed ure-
mic patients [1, 20] (and unpublished observations).
It is conceivable that hyperinsulinemia resulting
from peripheral insulin resistance stimulates hepat-
ic triglyceride synthesis in the presence of normal
or enhanced hepatic extraction of FFA. Using fat
tolerance tests, we have obtained indirect evidence
that triglyceride production may indeed be in-
creased in uremic patients on maintenance dialysis.
To avoid the inappropriateness of comparing sub-
jects with widely differing values of K2, we have
considered the relation between serum triglyceride
concentrations and K2 in subjects whose K2 are
less than 4%/mm. The regression lines between K2
and serum triglyceride concentrations for normal
subjects and dialysis patients are more or less
parallel but, at a given K2, dialysis patients had
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higher serum triglyceride concentrations, a finding
that can be interpreted as reflecting increased tri-
glyceride production. Direct evidence is, however,
lacking and experiments in uremic rats [71, 721 have
not provided confirmatory evidence. The clinical
relevance of these animal experiments is uncertain
because the uremic rat differs from the uremic man
in frequently manifesting hypercholesterolemia. As
Nikkila and Kekki [691 pointed out in the discussion
of the relation between triglyceride turnover and
serum triglyceride concentrations, subjects with
reduced Ymax and high Km (in other words, defec-
tive triglyceride removal) would have large in-
creases in serum triglyceride concentrations as a
result of small increases in triglyceride turnover.
This seems to be born out in the dietary study by
Sanfellipo, Swenson, and Reaven [671 in undialyzed
uremic patients in whom a 15% reduction in carbo-
hydrate intake produced a significant reduction in
serum triglyceride turnover rate. The traditional
diet prescribed for uremia is high in carbohydrate
and fat. Carbohydrates—sugar more than starch—
may induce hypertriglyceridemia [73], and a high fat
intake must present a further burden to the defec-
tive triglyceride removal mechanism. Increasing
dietary polyunsaturated : saturated (P:S) fatty acid
ratios have been shown to ameliorate the lipid
abnormalities in uremic patients on maintenance
dialysis [74]. It is possible that increasing the di-
etary P:S ratio increases triglyceride removal [75]
and, because serum triglyceride concentrations are
hyperbolically related to K2, relatively small in-
creases in K2 in hypertriglyceridaemic patients
could effect substantial reductions in serum tri-
glyceride concentrations. Therefore, the traditional
diet prescribed for uremic patients must receive
critical reappraisal.
Influence of dialysis, carnitine, and heparin. The
glucose and acetate in the dialysis fluid is signifi-
cant, especially in the context of continuous ambu-
latory peritoneal dialysis (CAPD) with its long
dwell-time [76]. The equilibration of peritoneal dial-
ysis fluid with plasma increases with time. With
longer dwell-times, the quantity of glucose trans-
ferred across the peritoneum is increased, thereby
constituting an important source of calorie intake
[77]. Hemodialysis with glucose-free dialysis fluid
has not produced encouraging results, and it would
appear that the contribution of dialysate glucose to
hypertriglyceridemia in hemodialysis patients is
probably not very significant [78, 79]. Dialysate
acetate, however, has a small yet significant [80]
contribution to the hypertriglyceridemia in some
hemodialysis patients, and it may assume greater
importance when high-flux membranes are more
frequently used because the acetate transfer could
amount to as much as 7.6 mmoles/min [81].
Conventional dialysis does not remove all "tox-
ic" compounds, and a poorly dialyzable inhibitor of
lipoprotein lipase in uremic plasma has been report-
ed [82]. Frequent and prolonged dialysis does not
consistently improve triglyceride removal; nor does
chronic hemodiafiltration [83], a procedure in which
substances of higher molecular weight are ultrafil-
tered across the artificial dialyzer membrane. Hut-
tunen et al [84], in a sequential study of six patients
in end-stage renal failure before and after the insti-
tution of dialysis, found that triglyceride and VLDL
concentrations decreased in five. The activity of
lipoprotein lipase and hepatic lipase were not affect-
ed by hemodialysis, and K2 (Intralipid) decreased
in four patients and increased in one patient after
the institution of dialysis.
Dialysis can cause appreciable loss of amino
acids and carnitine, a naturally occurring quarter-
nary amine whose major route of excretion is the
kidney, appears in significant quantities in the dialy-
sate [85]. Carnitine is important in the transfer of
long-chain free fatty acids across mitochondrial
membranes to the site of beta oxidation [86]. Con-
ceivably, carnitine deficiency, by reducing the oxi-
dation of FFA, would enhance triglyceride syn-
thesis in the presence of a constant rate of free fatty
acid influx. Carnitine can be synthesized in the liver
from lysine and methionine [87]. In this regard, it is
relevant to note that dialysis patients have low
plasma concentrations of lysine [88], and the myo-
cardial content of carnitine in uremic rats is dimin-
ished [89]. Tissue carnitine deficiency due to di-
etary lysine deficiency resulting in triglyceride
accumulation has been reported [90]. Carnitine has
been shown to improve hypertriglyceridemia in
subjects with normal renal function [91] as well as in
dialyzed [92] and nondialyzed [931 uremic patients.
Although seemingly promising, in high doses, carni-
tine can produce severe neuromuscular transmis-
sion problems [92], probably because of its structur-
al similarity to acetylcholine. The usefulness of this
compound in the long-term management of uremic
hyperlipoproteinaemia has yet to be evaluated.
Hemodialysis also entails the use of heparin. The
suggestion that prolonged heparinization in dialysis
patients depletes their enzyme stores is an interest-
ing speculation. Although heparinization for 2
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weeks in subjects with myocardial infarction did not
exhaust postheparin lipolytic activity [94], it is
worth noting that there was a successive decline in
enzyme activity in the first week during which
heparin was given. The activities of both lipoprotein
lipase and hepatic lipase decreased during a long-
term heparin infusion in three patients with deep-
vein thrombosis [84] and gradually returned to the
pretreatment level after termination of heparin infu-
sions. Decline in postheparin lipolytic activity does
occur in some dialysis patients [22], and it is entire-
ly conceivable that if the patients could not synthe-
size adequate amounts of lipoprotein lipase (? due
to insulin resistance) the releasable enzyme pool
would gradually diminish. This is the most likely
explanation for the finding that fasting hyperchylo-
micronemia occurs with unusual frequency [3, 95]
in hemodialysis patients and the occasional obser-
vation (personal observations) that a patient who
exhibits a type IV hyperlipoproteinemia on perito-
neal dialysis becomes type V when switched to
hemodialysis. Our demonstration that hemodialysis
patients had a smaller increase in K2 of Intralipid
after a standard dose of i.v. heparin than peritoneal
dialysis patients with similar serum triglyceride
concentrations, is also in keeping with such an
explanation [96]. Recently, heparin-free dialysis has
been reported by Japanese workers and no differ-
ence in postheparin lipolytic activity was detected
when eight subjects were switched from heparin-
free dialysis to conventional dialysis with heparin
[97]. Unfortunately, the numbers studied were
small, and the authors made no attempt to distin-
guish the normo- from hyper-triglyceridemic pa-
tients. This is crucial, because we have previously
shown that hypertriglyceridemic and normotri-
glyceridemic patients differ in their response to
heparin [21]. Sequential studies of dialysis with
heparin followed by heparin-free dialysis in sepa-
rate groups of normo- and hyper-triglyceridemic
patients would settle the controversy surrounding
the pathogenetic role of heparin in uremic
hypertriglyceridemia.
The influence of the duration of maintenance
dialysis in lipid abnormalities in uremic patients is
difficult to determine, for many patients change
from one modality of treatment to another, and
those who undergo renal transplantation are ex-
posed to large doses of corticosteroids. Our own
experience is that the prevalence of lipid abnormali-
ties does not seem to increase with the duration of
dialysis, though dialysis patients may have a higher
prevalence of hypertriglyceridemia than nondia-
lyzed patients in end-stage renal failure. Other
workers have reported that the prevalence of hyper-
lipidemia dropped from 33% in patients dialyzed for
less than 5 years to 16% in patients treated for more
than 5 years [13]. The explanation for this finding is
unclear.
Other factors. There is little information on cho-
lesterol absorption and disposal in uremic patients.
This is perhaps not surprising in view of the fact
that the predominant lipoprotein abnormalities are
type IV. Studies on the uptake of low-density
lipoprotein (LDL) by cells from uremic patients
are certainly worthwhile, however, for hypertrigly-
ceridemia is only one of the risk factors for car-
diovascular disease in these patients and intracellu-
lar cholesterol synthesis is regulated by the LDL
uptake via high affinity cellular receptors [98].
The reduced lecithin-cholesterol-acyl-transferase
(LCAT) activity [99] in uremia is unexpected, be-
cause LCAT activity is often raised in hypertrigly-
ceridemic states [100]. It may be due to the low
HDL, because HDL is the preferred substrate [101]
and one of its apoproteins is an activator of LCAT
[102]. It may also contribute to the defective triglyc-
eride removal, for it has been postulated that LCAT
is essential in processing the excess surface materi-
al during the breakdown of triglyceride-rich parti-
cles [103]. It has been suggested that HDL with the
aid of LCAT is responsible for the centripetal
transfer of cholesterol from peripheral tissues to the
liver [104, 105]. HDL has been demonstrated to
modify the interaction between endothelial cells
and LDL [106]. There is a negative correlation
between HDL cholesterol concentrations and the
degree of coronary vessel occlusion assessed angio-
graphically [107]. Such studies are most needed in
uremic patients. Uremic patients have many factors
against them. They are usually hypertensive, and
their vessels calcify, probably as a result of hyper-
parathyroidism. In such a setting, it is perhaps
surprising not to find an even higher incidence of
coronary heart disease. Thus, the reports of in-
creased availability of prostacyclin to vascular en-
dothelium in uremia are most intriguing [108, 109].
Prostacyclin is an important local hormone against
thrombosis [110], and it may partly reduce the
incidence of coronary thrombosis in this high-risk
population.
The multiple pharmacologic agents uremic pa-
tients receive also require attention. Sex hormone
preparations, androgens used in the treatment of
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anemia, and estrogens used to prevent excessive
menstrual loss during hemodialysis, are known to
produce hypertriglyceridemia by increasing VLDL
synthesis [25]. Uremic patients often receive thia-
zide diuretics and beta-adrenergic receptor blocking
agents for the treatment of hypertension. Thiazide
diuretics can produce hyperlipidemia [111, 1121,
apart from causing impairment in glucose tolerance.
The metabolic effects of beta-adrenergic receptor
blocking agents are complex, and acute effects may
be different from long-term effects; for instance,
reduced postheparin lipolytic activity has been re-
ported in patients with presumably normal renal
function after treatment with beta-adrenergic block-
ing agents [1131. Most dialysis patients can be taken
off antihypertensive treatment, and the contribution
of these therapeutic agents to their hypertriglyceri-
demia is probably trivial. The role played by these
agents in the hypertriglyceridemia of undialyzed
uremic patients may be significant, however, and
requires further evaluation.
What happens after transplantation? Transplan-
tation substitutes one set of problems with another.
The incidence of cardiovascular complications in
transplant patients remains high, accounting for
about 40% of the deaths that occur within 3 months
of transplantation [91. Thrombotic episodes appear
to be relatively common [10]. The lipid profile
changes, with a rise in cholesterol concentration
alone or in combination with triglycerides [5—71.
Type lIb hyperlipidemia is at least as common as
type IV. Plasma HDL cholesterol concentrations
often return to normal or near normal. There is little
doubt that steroids, by promoting insulin resist-
ance, contribute to the pathogenesis of the lipid
abnormalities. But, the relative importance of in-
creased hepatic secretion of VLDL and decreased
peripheral triglyceride removal remains unsettled.
Reduced Intralipid clearance and total postheparin
lipolytic activities [221 have been reported in renal
allograft recipients and reduced adipose tissue lipo-
protein lipase in animals given steroids [114]. On
the other hand, there is evidence that triglyceride
production by the liver is increased. We, like others
[1151, have found that the cumulative steroid dose is
higher in hyperlipemic than in normolipemic renal
allograft recipients [1161. In addition, we have dem-
onstrated a significant positive correlation between
serum triglyceride concentrations and plasma im-
munoreactive insulin levels (Fig. 3). In this regard,
it is interesting to note that in acute experiments in
rats the rate-limiting enzymes of lipogenesis, acetyl
CoA carboxylase and free fatty acid synthetase,
I I I I I
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Fig. 3. Correlation between serum triglyceride and plasma
immunoreaclive insulin concentrations in renal allograft recipi-
ents (from CHAN et a! [1161). A highly significant (P < 0.001)
positive correlation exists between the two variables for both
male (open circles) and female (closed circles) patients.
increase after steroid administration [1151. The rise
in immunoreactive insulin concentration precedes
the rise in the concentrations of these rate-limiting
enzymes, and in alloxan diabetic rats no rise in
acetyle CoA carboxylase activity can be demon-
strated. We have also shown in 19 renal allograft
recipients that K2 correlates inversely with plasma
immunoreactive insulin levels and that at a given
K2, renal allograft recipients have higher serum
triglyceride concentrations than do normal sub-
jects, probably reflecting increased triglyceride pro-
duction (unpublished observations). Although tri-
glyceride production has not been measured direct-
ly, the finding of high free fatty acid concentrations
[1181 and a positive correlation between serum
triglyceride concentrations and insulin would indi-
cate that increased hepatic production of triglycer-
ides is the predominant factor. This is probably the
reason why patients can be rendered normotrigly-
ceridemic by caloric restriction [115]. The finding of
normal postheparin lipoprotein lipase and hepatic
lipase after renal transplantation is also consistent
with this view [37]. For many transplant patients,
increased hepatic production of VLDL coupled
with near normal conversion of VLDL to LDL
probably explains the high prevalence of type lIa
and type lIb in these patients. Whichever mecha-
nism predominates, it would appear that insulin
resistance is the center of the problem. A search for
nonsteroidal immunosuppressive agents must con-
tinue. In the meantime, other factors which may be
operating, for instance, diuretics and beta-adrener-
gic receptor blocking agents, must also receive
attention [116].
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Fig. 4. Pathogenesis of uremic hypertriglyceri-
demia.
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Summary. Lipid abnormalities in uremic and
dialysis patients are due to multiple factors. Defec-
tive triglyceride removal as a result of decreased
enzyme/activator or increased inhibitor concentra-
tions plays an important role. Increased triglyceride
production probably also occurs in some patients.
Insulin resistance may contribute to both decreased
removal and increased production of triglycerides.
Whether this resistance could be ascribed to a
reduced number of cellular receptors for insulin
[119] remains to be clarified. High dietary carbohy-
drate and fat intake undoubtedly impose further
burdens on the defective triglyceride removal
mechanism. Contributions due to dialysate glucose
will assume greater proportions now that CAPD is
widely practised. The complexity of the problem is
schematically summarized in Fig. 4.
Further insight into the pathogenesis of uremic
hypertriglyceridemia is likely to come from mea-
surements of plasma lipoprotein lipase activator
concentrations with parallel determinations of in
vivo triglyceride clearances and in vitro postheparin
lipolytic activities, particularly in normotriglyceri-
demic and hypertriglyceridemic patients studied as
separate groups. The contribution of hypertriglyc-
eridemia and low HDL concentrations to the inci-
dence of coronary heart disease has to be carefully
assessed in the light of other risk factors such as
hypertension, left ventricular hypertrophy, hyper-
uncemia, and smoking habits. Until such work is
done, attempts to correct the lipid abnormalities on
a long-term basis with potentially toxic therapeutic
agents are probably not warranted. After renal
transplantation, increased triglyceride production
due to hyperinsulinemia resulting from peripheral
insulin resistance owing to high steroid therapy
plays the dominant role. Although the search for a
nonsteroidal immunosuppressive agent continues,
the most reasonable approach to correct hyperlipi-
demia after renal transplantation appears to be
calorie restriction. Whether the correction of lipid
abnormalities reduces cardiovascular mortality in
these patients remains to be seen.
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